Brian Durkin Net Worth

The estimated Net Worth of Brian L Durkin is at least $783 Thousand dollars as of 25 March 2019. Mr. Durkin owns over 475 units of AbbVie stock worth over $745,642 and over the last few years he sold ABBV stock worth over $37,853. In addition, he makes $0 as Vice President and Controller at AbbVie.

Mr. Durkin ABBV stock SEC Form 4 insider trading

Brian has made over 1 trades of the AbbVie stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 475 units of ABBV stock worth $37,853 on 25 March 2019.

The largest trade he’s ever made was selling 475 units of AbbVie stock on 25 March 2019 worth over $37,853. On average, Brian trades about 119 units every 0 days since 2019. As of 25 March 2019 he still owns at least 9,121 units of AbbVie stock.

You can see the complete history of Mr. Durkin stock trades at the bottom of the page.

Brian Durkin biography

Brian L. Durkin serves as Vice President, Controller of the Company. Mr. Durkin previously served as Vice President, Internal Audit from 2016 to 2018. Prior to joining AbbVie, he served as Vice President of Finance and Division Controller for Abbott’s Vision Care business from 2009 to 2016 and Controller Pharmaceutical Research and Development from 2005 to 2009. Mr. Durkin joined Abbott in 1986.

How old is Brian Durkin?

Brian Durkin is 58, he’s been the Vice President and Controller of AbbVie since 2018. There are 9 older and 11 younger executives at AbbVie. The oldest executive at AbbVie, Inc. is Edward Liddy, 73, who is the Independent Director.

What’s Brian Durkin’s mailing address?

Brian’s mailing address filed with the SEC is 1 NORTH WAUKEGAN ROAD, , NORTH CHICAGO, IL, 60064.

Insider trading at AbbVie

Over the last 7 years, insiders at AbbVie have traded over $114,130,047 worth of AbbVie stock and bought 207,390 units worth $13,938,118 . The most active insider traders include Richard A Gonzalez, Frederick H Waddell, and Glenn F Tilton. On average, AbbVie executives and independent directors trade stock every 21 days with the average trade being worth of $2,604,067. The most recent stock trade was executed by Timothy J. Richmond on 27 September 2019, trading 15,515 units of ABBV stock currently worth $1,163,935.

What does AbbVie do?

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson’s disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

What does AbbVie’s logo look like?

Complete history of Mr. Durkin stock trades at AbbVie

AbbVie executives and stock owners

AbbVie executives and other stock owners filed with the SEC include:

• Richard Gonzalez, Chairman of the Board, Chief Executive Officer
• Laura Schumacher, Vice Chairman, External Affairs and Chief Legal Officer
• Carlos Alban, Vice Chairman, Chief Commercial Officer
• William Chase, Executive Vice President – Finance and Administration
• Michael Severino, President, Vice Chairman
• Timothy Richmond, Chief Human Resource Officer, Executive Vice President
• Robert Michael, Chief Financial Officer, Senior Vice President
• Glenn Tilton, Lead Independent Director
• Robert Alpern, Independent Director
• Edward Rapp, Independent Director
• Frederick Waddell, Independent Director
• Melody Meyer, Independent Director
• William Burnside, Independent Director
• Roxanne Austin, Independent Director
• Brett Hart, Independent Director
• Edward Liddy, Independent Director
• Rebecca Roberts, Independent Director
• Brian Durkin, Vice President, Controller
• Jeffrey Stewart, Senior Vice President, U.S. Commercial Operations
• Nicholas Donoghoe, Senior Vice President – Enterprise Innovation
• Azita Saleki-Gerhardt, Executive Vice President – Operations
• Henry Gosebruch, Executive Vice President, Chief Strategy Officer
• Thomas A. Hurwich, VP, Controller
• Roy S Roberts, Director
• Laboratories Abbott, 10% owner
• John M. Leonard, SVP, Chief Scientific Officer